Cargando…

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2

BACKGROUND: The COVID-19 pandemic continues to pose a significant worldwide threat to human health, as emerging SARS-CoV-2 Omicron variants exhibit resistance to therapeutic antibodies and the ability to evade vaccination-induced antibodies. Here, we aimed to identify human antibodies (hAbs) from co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Hsiao-Ling, Liang, Kang-Hao, Lu, Ruei-Min, Kuo, Ting-Wen, Lin, Yi‑Ling, Wu, Han-Chung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388472/ https://www.ncbi.nlm.nih.gov/pubmed/37525188 http://dx.doi.org/10.1186/s12929-023-00955-x

Ejemplares similares

Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants
por: Ju, Bin, et al.
Publicado: (2023)

Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice
por: Lu, Ruei-Min, et al.
Publicado: (2023)

Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants
por: Duty, J. Andrew, et al.
Publicado: (2022)

Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients
por: Chen, Jun, et al.
Publicado: (2023)

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
por: Moriyama, Saya, et al.
Publicado: (2023)

Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
por: Changrob, Siriruk, et al.
Publicado: (2023)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
por: Zhu, Ka-Li, et al.
Publicado: (2023)

Neutralizing Antibodies against the SARS-CoV-2 Ancestral Strain and Omicron BA.1 Subvariant in Dogs and Cats in Mexico
por: Dehesa-Canseco, Freddy, et al.
Publicado: (2023)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
por: Shah, Masaud, et al.
Publicado: (2023)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Comparison of the replication and neutralization of different SARS‐CoV‐2 Omicron subvariants in vitro
por: Zhang, Yaqing, et al.
Publicado: (2023)

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
por: Li, Mingxi, et al.
Publicado: (2022)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination
por: Chi, Xiangyang, et al.
Publicado: (2022)

A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
por: Zhou, Biao, et al.
Publicado: (2022)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
por: Yang, Jingyun, et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
por: Desautels, Thomas A., et al.
Publicado: (2023)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
por: Ohashi, Hirofumi, et al.
Publicado: (2022)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
por: Ke, Hanzhong, et al.
Publicado: (2022)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants
por: Wang, Junxiang, et al.
Publicado: (2022)

Fortuitous Somatic Mutations during Antibody Evolution Endow Broad Neutralization against SARS-CoV-2 Omicron Variants
por: Wu, Jianbo, et al.
Publicado: (2022)

Fortuitous somatic mutations during antibody evolution endow broad neutralization against SARS-CoV-2 Omicron variants
por: Wu, Jianbo, et al.
Publicado: (2023)

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
por: Lee, I-Jung, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern
por: Wang, Gang, et al.
Publicado: (2022)

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
por: Cho, Junhyung, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
por: Miyashita, Naoyuki, et al.
Publicado: (2023)

Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron
por: Wang, Siling, et al.
Publicado: (2022)

Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants
por: Chi, Xiangyang, et al.
Publicado: (2023)

Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
por: Wen, Kun, et al.
Publicado: (2023)

Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2
por: Pastorio, Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_puq15u1lq0atbnpgblj27nosck